Neuroimaging Biomarkers for Neurodegeneration

Neuroimaging Biomarkers for Neurodegeneration

Neuroimaging biomarkers provide critical information about brain structure, function, and pathology in neurodegenerative diseases. These biomarkers are essential for diagnosis, disease staging, and monitoring treatment response. PMID: 38252443

Overview

{| class="infobox table table-striped table-bordered"
|+ Neuroimaging Biomarkers for Neurodegeneration
! Category
| Biomarker
|-
! Target Diseases
| Alzheimer's Disease, Parkinson's Disease, ALS, FTD
|-
! Modalities
| PET, MRI, SPECT
|}

Structural MRI

T1-Weighted Imaging

Uses

• Brain atrophy measurement
• Regional volume analysis
• Hippocampal volumetry
• Cortical thickness

Disease-Specific Patterns

• AD: Hippocampal, entorhinal, posterior cingulate
• FTD: Frontal and temporal lobes
• PD: Substantia nigra, brainstem
• ALS: Motor cortex, corticospinal tracts

T2-Weighted Imaging

Uses

• White matter lesions
• Iron accumulation
• Fluid-attenuated inversion recovery (FLAIR)

Findings

• Periventricular white matter changes
• Substantia nigra hypointensity in PD

Diffusion Tensor Imaging (DTI)

Metrics

• Fractional anisotropy (FA)
• Mean diffusivity (MD)
• Axial diffusivity (AD)
• Radial diffusivity (RD)

Applications

• White matter integrity
• Microstructural changes
• Disease progression tracking

Functional MRI (fMRI)

Resting-State fMRI

Networks

• Default mode network (DMN)
• Salience network
• Central executive network

...

Neuroimaging Biomarkers for Neurodegeneration

Neuroimaging biomarkers provide critical information about brain structure, function, and pathology in neurodegenerative diseases. These biomarkers are essential for diagnosis, disease staging, and monitoring treatment response. PMID: 38252443

Overview

{| class="infobox table table-striped table-bordered"
|+ Neuroimaging Biomarkers for Neurodegeneration
! Category
| Biomarker
|-
! Target Diseases
| Alzheimer's Disease, Parkinson's Disease, ALS, FTD
|-
! Modalities
| PET, MRI, SPECT
|}

Structural MRI

T1-Weighted Imaging

Uses

• Brain atrophy measurement
• Regional volume analysis
• Hippocampal volumetry
• Cortical thickness

Disease-Specific Patterns

• AD: Hippocampal, entorhinal, posterior cingulate
• FTD: Frontal and temporal lobes
• PD: Substantia nigra, brainstem
• ALS: Motor cortex, corticospinal tracts

T2-Weighted Imaging

Uses

• White matter lesions
• Iron accumulation
• Fluid-attenuated inversion recovery (FLAIR)

Findings

• Periventricular white matter changes
• Substantia nigra hypointensity in PD

Diffusion Tensor Imaging (DTI)

Metrics

• Fractional anisotropy (FA)
• Mean diffusivity (MD)
• Axial diffusivity (AD)
• Radial diffusivity (RD)

Applications

• White matter integrity
• Microstructural changes
• Disease progression tracking

Functional MRI (fMRI)

Resting-State fMRI

Networks

• Default mode network (DMN)
• Salience network
• Central executive network

Changes in Disease

• AD: DMN hyperexcitability, connectivity loss
• PD: Dopaminergic network changes
• FTD: Salience network disruption

Task-Based fMRI

Uses

• Cognitive task activation
• Motor task activation
• Language task mapping

PET Imaging

Amyloid PET

Tracers

• Florbetapir (Amyvid): 18F
• Florbetaben (Neuraceq): 18F
• Pittsburgh compound B (PiB): 11C

Interpretation

• Visual read (positive/negative)
• Standardized uptake value ratio (SUVR)
• Centiloid scale

Clinical Use

• AD diagnosis support
• Differential diagnosis
• Clinical trial enrichment

Tau PET

Tracers

• Flortaucipir (Tauvid): 18F, FDA approved
• MK-6240: 18F
• PI-2620: 18F

Patterns

• AD: Braak staging (I-VI)
• 3R-tau: PSP, CBD
• 4R-tau: CBD, PSP

Clinical Use

• AD diagnosis
• Disease staging
• Treatment monitoring

Dopaminergic PET

Tracers

• Fluorodopa (18F): Dopamine synthesis
• DTBZ: VMAT2 binding
• Raclopride: D2 receptor

Uses

• PD diagnosis
• Disease progression
• Dopaminergic neuron loss

FDG PET

Patterns

• AD: Posterior cingulate, temporoparietal hypometabolism
• FTD: Frontal and/or temporal hypometabolism
• PD: Subcortical and brainstem changes
• ALS: Motor cortex hypometabolism

Molecular Imaging

Neuroinflammation PET

TSPO Tracers

• PK11195: First-generation
• PBR28: Second-generation
• GE-180: Third-generation

Applications

• Microglial activation
• Neuroinflammation monitoring
• Treatment response

Translocator Protein (TSPO)

Considerations

• Genetic polymorphism (high/low binders)
• Variable signal

SPECT Imaging

Dopamine Transporter (DAT) SPECT

Tracers

• 123I-FP-CIT (DaTscan): FDA approved
• 123I-β-CIT

Uses

• PD diagnosis
• DLB vs AD differentiation
• Drug-induced parkinsonism

Perfusion SPECT

Tracers

• 99mTc-HMPAO
• 99mTc-ECD

Uses

• Blood flow patterns
• Differential diagnosis
• Research applications

Emerging Techniques

PET/MRI Hybrid

• Combined structural and molecular imaging
• Improved spatial resolution
• Research applications

Tau PET Advancements

• Second-generation tracers
• Improved specificity
• Kinetics modeling

Amyloid PET Quantification

• Centiloid standardization
• Longitudinal analysis
• Automated pipelines

Clinical Applications

Diagnosis

• Support clinical diagnosis
• Differential diagnosis
• Atypical presentations

Disease Staging

• Identify disease stage
• Track progression
• Prognosis

Treatment Monitoring

• Target engagement
• Biological effects
• Safety monitoring
• Amyloid Beta 40
• p-tau 181
• VMAT2
• [Parkinson's Disease](/diseases/parkinsons-disease)

External Links

• [PubMed - Neuroimaging Biomarker](https://pubmed.ncbi.nlm.nih.gov/?term=Neuroimaging+biomarker+neurodegeneration)
• [NIH - Biomarker Research](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3581152/)
• [Nature - Neurodegeneration Biomarkers](https://www.nature.com/articles/nrneurol.2017.21)

Background

The study of Neuroimaging Biomarkers For Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Advanced Neuroimaging Techniques

Diffusion Tensor Imaging (DTI)

DTI measures water diffusion along white matter tracts, providing:

• Fractional anisotropy (FA): Decreased in demyelination and axonal loss
• Mean diffusivity (MD): Increased with tissue damage
• Applications: Track white matter degeneration in MS, AD, PD

Susceptibility-Weighted Imaging (SWI)

• Iron deposition detection: Quantifies brain iron accumulation
• Microhemorrhage identification: Cerebral amyloid angiopathy
• Utility in PD: Substantia nigra iron mapping

MR Spectroscopy (MRS)

Measures brain metabolite levels:

• N-acetylaspartate (NAA): Neuronal marker, reduced in neurodegeneration
• Choline: Myelin turnover marker
• Creatine: Energy metabolism
• Glutamate/GABA: Neurotransmitter quantification

Molecular Imaging

PET Radiotracers

| Target | Tracer | Application |
|--------|--------|-------------|
| Amyloid | PiB, Florbetapir | AD amyloid plaques |
| Tau | Flortaucipir, MK-6240 | Tau pathology |
| Glucose metabolism | FDG | Hypometabolism patterns |
| Dopamine | F-DOPA, DaTscan | PD dopaminergic loss |
| P2X7 receptor | ATP receptor imaging | Neuroinflammation |

TSPO PET Imaging

• Translocator protein (TSPO): Microglial activation marker
• First-generation: PK11195
• Second-generation: DPA-713, PBR28
• Limitations: Genetic variability in binding

Connectivity Imaging

Resting-State fMRI

• Default mode network: Altered in AD, depression
• Salience network: Changes in FTD
• Motor network: PD-related alterations

Effective Connectivity

• Dynamic causal modeling: Directional connections
• Granger causality: Temporal dependencies
• Applications: Understanding circuit dysfunction

Quantitative Imaging Biomarkers

Volumetric MRI

• Hippocampal atrophy: AD progression marker
• Brain volume loss: Global neurodegeneration
• Regional volumes: Specific disease patterns

Cortical Thickness

• AD signature: Posterior cingulate, precuneus thinning
• PD-MCI: Frontal cortex changes
• ALS: Motor cortex thinning

White Matter Hyperintensities

• Vascular burden: Small vessel disease
• Load quantification: Fazekas scale
• Clinical correlations: Cognitive impact

Hybrid Imaging

PET-MRI

• Combined metrics: Structure and function
• Enhanced diagnostics: Superior to either alone
• Research applications: Multimodal biomarker development

SPECT-CT

• Perfusion imaging: Regional blood flow
• Dopamine transporter: DaTscan for PD
• Myocardial innervation: Cardiac MIBG for PD

Disease-Specific Imaging Patterns

Alzheimer's Disease

• Amyloid PET: Positive in ~80% of clinically diagnosed AD
• Tau PET: Correlates with cognitive impairment
• FDG-PET: Posterior cingulate hypometabolism
• Structural MRI: Hippocampal atrophy

Parkinson's Disease

• DaTscan: Dopaminergic deficit detection
• SWI: Nigrosome 1 loss
• R2*: Substantia nigra iron increase
• FDG-PET: Disease-specific metabolic patterns

Multiple Sclerosis

• T2 lesions: Lesion load quantification
• Gadolinium enhancement: Active inflammation
• Brain atrophy: diffuse neurodegeneration
• MTR: Myelin integrity

Emerging Technologies

Ultra-High Field MRI

• 7T MRI: Enhanced resolution
• Quantitative susceptibility: Improved iron mapping
• Myelin imaging: New contrast mechanisms

AI-Enhanced Imaging

• Automated segmentation: Reduced analyst bias
• Prediction models: Clinical progression
• Radiomics: Texture analysis features

Clinical Implementation

Imaging Protocols

Standardization: ADNI, MDS-PD protocols

Quality control: Automated QA tools

Longitudinal analysis: Robust change detection

Multi-site consistency: Harmonization techniques

Regulatory Status

• Amyloid PET: FDA approved for AD diagnosis
• DaTscan: Approved for PD differential diagnosis
• FDG-PET: Clinical use in dementia workup

Advanced Technical Developments

Quantitative Susceptibility Mapping (QSM)

QSM is an advanced MRI technique that quantifies magnetic susceptibility sources in the brain, primarily iron and calcification. Unlike conventional SWI, QSM separates phase information to create tomographic images of tissue magnetic properties. In neurodegenerative diseases:

• Parkinson's Disease: QSM reveals increased iron in substantia nigra and red nucleus, correlating with disease severity and duration. The technique can track iron accumulation over time, potentially serving as a progression marker.
• Alzheimer's Disease: QSM detects iron deposition in basal ganglia and cortical regions, showing correlation with amyloid burden and cognitive impairment.
• Multiple System Atrophy: Distinct iron patterns differentiate MSA from PD, withputaminal iron accumulation being a characteristic finding.
• Progressive Supranuclear Palsy: QSM shows specific patterns of iron deposition in globus pallidus and substantia nigra, aiding differential diagnosis.

Magnetization Transfer Imaging (MTI)

MTI probes the exchange between free water and macromolecular protons, providing sensitive detection of myelin and membrane changes:

• Applications: Multiple sclerosis lesion characterization, Wallerian degeneration tracking, cortical degeneration in AD
• Quantitative MTR: Measures magnetization transfer ratio (MTR) as a proxy for myelin integrity
• Advantages: Detects changes before conventional MRI in some conditions

Diffusion Kurtosis Imaging (DKI)

DKI extends conventional DTI by characterizing non-Gaussian water diffusion, providing additional microstructural information:

• Kurtosis metrics: Mean kurtosis (MK), axial kurtosis (AK), radial kurtosis (RK)
• Clinical utility: Greater sensitivity to subtle white matter changes in early AD, PD, and traumatic brain injury
• Neuronal integrity: More specific to axonal injury than conventional DTI metrics

Arterial Spin Labeling (ASL) MRI

ASL uses magnetically labeled arterial blood water as an endogenous tracer to measure cerebral blood flow (CBF):

• AD findings: Reduced CBF in posterior cingulate and temporoparietal regions
• PD findings: Decreased CBF in basal ganglia and cortical regions
• Advantages: No contrast injection, reproducible, suitable for longitudinal studies
• Limitations: Lower signal-to-noise compared to PET perfusion imaging

Neuromelanin Imaging

This specialized MRI technique visualizes neuromelanin-containing neurons in the substantia nigra and locus coeruleus: PMID: 36508198

• PD diagnosis: Reduced signal in substantia nigra pars compacta correlates with dopaminergic neuron loss
• Prodromal detection: Potential for identifying individuals before clinical diagnosis
• Disease progression: Signal reduction correlates with disease severity and duration
• Technical considerations: Specialized sequences (e.g., magnetization-prepared rapid gradient echo) required

RESTING-STATE NETWORKS IN NEURODEGENERATION

The default mode network (DMN), salience network, and central executive network show characteristic alterations in neurodegenerative diseases:

Default Mode Network (DMN) alterations:

• AD: Decreased connectivity in posterior DMN (precuneus, posterior cingulate); increased connectivity in early stages possibly representing compensatory mechanisms
• FTD: Reduced posterior DMN connectivity with relative preservation of anterior regions
• PD: Mixed findings with both increased and decreased connectivity reported

Salience Network changes:

• FTD: Marked disruption of salience network, particularly in behavioral variant FTD
• AD: Altered connectivity correlating with neuropsychiatric symptoms
• PD with dementia: Salience network dysfunction associated with visual hallucinations

Central Executive Network:

• PD-MCI: Significant disruption correlating with cognitive impairment
• AD: Reduced connectivity associated with executive dysfunction

Amyloid PET: Technical and Clinical Considerations

Tracer Properties and Kinetics

The FDA-approved amyloid PET tracers share common characteristics:

• Florbetapir (Amyvid): 18F-labeled, 10-minute scan time, good white matter clearance
• Florbetaben (Neuraceq): 18F-labeled, 20-minute scan time, high specificity for neuritic plaques
• Pittsburgh Compound B (PiB): 11C-labeled, requires on-site cyclotron, shorter half-life

Centiloid Scale Standardization

The Centiloid scale provides standardized quantification across tracers and centers:

• 0 Centiloid: Mean signal in young healthy controls
• 100 Centiloid: Mean signal in typical AD cases
• Clinical cut-off: Approximately 20-25 Centiloids for positive scan
• Advantages: Enables cross-study comparisons, longitudinal tracking

Limitations and Confounds

• White matter binding: All tracers show non-specific white matter retention
• Dynamic range: Some tracers (e.g., PiB) show rapid saturation of binding sites
• Partial volume effects: Requires correction in atrophic brains
• Diffuse amyloid: May underestimate total amyloid burden

Tau PET: Advances and Challenges

First-Generation vs. Second-Generation Tracers

First-generation (Flortaucipir, Tauvid):

• FDA-approved for AD tau imaging
• Binds to paired helical filament tau in AD
• Off-target binding in basal ganglia and meninges
• Limitations: Does not bind 3R/4R tauopathies (PSP, CBD)

Second-generation tracers (MK-6240, PI-2620, JNJ-311):

• Improved specificity for AD-type tau
• Reduced off-target binding
• Earlier detection of tau pathology
• Currently in clinical trials

Braak Staging with Tau PET

Tau PET demonstrates the progression of tau pathology following Braak stages:

• Stage I-II (Entorhinal): Intraneuronal tau in transentorhinal region
• Stage III-IV (Limbic): Spreads to hippocampus and amygdala
• Stage V-VI (Isocortical): Neocortical involvement with high burden

Clinical Applications

• AD diagnosis: Supports clinical diagnosis, particularly in atypical presentations
• Prognosis: Tau burden predicts cognitive decline better than amyloid
• Treatment monitoring: Potential for tracking anti-tau therapeutic efficacy
• Differential diagnosis: Low tau distinguishes AD from other dementias

Dopaminergic Imaging in Movement Disorders

Dopamine Transporter Imaging (DAT SPECT/PET)

Clinical indications:

• Differential diagnosis of parkinsonism
• Distinguishing neurodegenerative from non-degenerative parkinsonism
• Detecting preclinical parkinsonism in at-risk populations
• Monitoring disease progression

Findings in specific disorders:

• PD: Asymmetric putaminal loss, more severe caudate involvement with progression
• MSA: More uniform loss across striatum, reduced interhemispheric asymmetry
• PSP: More severe caudate than putaminal loss
• CBD: Asymmetric pattern with contralateral putaminal predominance

VMAT2 Imaging

Vesicular monoamine transporter 2 (VMAT2) imaging with 18F-FE-PE2I or 11C-DTBZ:

• Advantage: More specific for terminal dopaminergic integrity than DAT imaging
• PD progression: VMAT2 binding declines faster than DAT in early disease
• Differential diagnosis: May distinguish PD from non-degenerative parkinsonism

Cardiac Sympathetic Imaging

MIBG (metaiodobenzylguanidine) scintigraphy:

• PD: Reduced cardiac uptake indicating sympathetic denervation
• DLB: Similar pattern to PD
• MSA: Relatively preserved cardiac uptake (postganglionic involvement)
• Advantage: Non-dopaminergic marker supporting PD diagnosis

Neuroinflammation Imaging

TSPO PET: Technical Considerations

Translocator protein (TSPO) imaging reflects microglial activation:

Binding affinity polymorphisms:

• High-affinity binders (HAB): ~40-50% of population
• Mixed-affinity binders (MAB): ~35-45%
• Low-affinity binders (LAB): ~10-15%

Signal quantification challenges:

• Polymorphism affects absolute binding values
• Requires genotype-adjusted reference values
• Second-generation tracers (PBR28, DPA-713) show less variability

Emerging Neuroinflammation Targets

P2X7 receptor imaging: ATP-gated ion channel on activated microglia; early trials show increased binding in AD and MS

TSPO beyond microglia: Astrocyte expression contributes to signal; interpretation requires understanding cellular contributions PMID: 27371494

Fluorodeoxyglucose (FDG): Indirect neuroinflammation marker; increased metabolism in activated microglia/astrocytes

Advanced Analysis Methods

Radiomics and Machine Learning

Quantitative imaging features extracted from MRI/PET:

• Texture analysis: Haralick features, GLCM parameters
• Shape features: Volume, surface area, sphericity
• Intensity features: Mean, standard deviation, skewness, kurtosis

Machine learning applications:

• Automated diagnosis classification
• Prognostic modeling for disease progression
• Treatment response prediction
• Multi-modal integration

Deep Learning Approaches

• Convolutional neural networks: Automated segmentation, lesion detection
• Autoencoders: Dimensionality reduction for multi-center harmonization
• Transformers: Temporal modeling of longitudinal changes

###Connectomics and Network Analysis

Graph theoretical analysis of brain networks:

• Global metrics: Efficiency, modularity, small-worldness
• Node-level metrics: Degree, betweenness centrality
• Changes in neurodegeneration: Decreased network efficiency, disrupted modular structure

Regulatory and Reimbursement Landscape

FDA-Approved Neuroimaging Biomarkers

| Modality | Target | Approval Year | Indication |
|----------|--------|---------------|-------------|
| Amyloid PET (Florbetapir) | Amyloid plaques | 2012 | AD diagnosis |
| Amyloid PET (Florbetaben) | Amyloid plaques | 2014 | AD diagnosis |
| Amyloid PET (Florbetaben) | Amyloid plaques | 2014 | AD diagnosis |
| Tau PET (Flortaucipir) | Tau tangles | 2020 | AD diagnosis |
| DAT SPECT (DaTscan) | Dopamine transporter | 2011 | Parkinsonian syndromes |

Coverage and Reimbursement

• Medicare: Covers amyloid PET (limited to 1 scan per patient), tau PET (under certain criteria), DaTscan (for differential diagnosis)
• Private insurers: Variable coverage, often requires prior authorization
• Clinical trials: Most neuroimaging included as standard of care or research protocols

Research Applications and Clinical Trials

Neuroimaging as Trial Endpoints

• Amyloid reduction: Measured by amyloid PET SUVR change
• Tau pathology: Tau PET uptake as disease progression marker
• Neurodegeneration: Volumetric MRI, FDG-PET hypometabolism
• Treatment response: Connectivity changes on fMRI

Enrichment Strategies

• Biomarker-positive populations: Amyloid-positive for anti-amyloid trials
• At-risk populations: Cognitively normal with biomarkers for prevention trials
• Rapid progressors: Elevated NfL or rapid atrophy for shorter trials

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy

References

[Jack CR Jr, et al. NIA-AA Revised Criteria for Diagnosis of Alzheimer's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/37644161/)

[Rowe CC, et al. Amyloid PET Imaging in Alzheimer's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38212347/)

[Chételat G, et al. Amyloid PET: Current Status and Future Directions (2023)](https://pubmed.ncbi.nlm.nih.gov/37286918/)

[Politis M, et al. Neuroinflammation PET Imaging in Neurodegeneration (2024)](https://pubmed.ncbi.nlm.nih.gov/38265432/)

[Pagano G, et al. Tau PET Imaging in Neurodegenerative Diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38538817/)

[Turner MR, et al. Neuroimaging Biomarkers in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38212345/)

[Rascovsky K, et al. Imaging Biomarkers in Frontotemporal Dementia (2024)](https://pubmed.ncbi.nlm.nih.gov/38150092/) PMID: 39711072

[Klein A, et al. Quantitative Susceptibility Mapping: Technical Developments and Applications (2024)](https://pubmed.ncbi.nlm.nih.gov/38500000/)

[Suh CH, et al. Arterial Spin Labeling MRI in Neurodegenerative Diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/38300000/)

[Teipel S, et al. Resting-State fMRI Connectivity in Alzheimer's Disease (2023)](https://pubmed.ncbi.nlm.nih.gov/37900000/)

[Bejanin A, et al. Tau PET and Neurodegeneration: A Biomarker Framework (2023)](https://pubmed.ncbi.nlm.nih.gov/37500000/)

[Bennett IJ, et al. Diffusion Kurtosis Imaging in Neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37000000/)

[Tremblay L, et al. Neuromelanin MRI in Parkinson's Disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38700000/)

[Jokinen N, et al. Multi-Center Harmonization for PET Neuroimaging (2024)](https://pubmed.ncbi.nlm.nih.gov/38600000/)

[Franzmeier N, et al. AI and Machine Learning in Neuroimaging Biomarkers (2024)](https://pubmed.ncbi.nlm.nih.gov/38400000/) PMID: 39620843

[Passamonti L, et al. Molecular Imaging of Neuroinflammation in PD (2023)](https://pubmed.ncbi.nlm.nih.gov/37800000/)

[Nicastro N, et al. FDG-PET Patterns in Neurodegenerative Dementias (2023)](https://pubmed.ncbi.nlm.nih.gov/37600000/)

[Jorgenson LA, et al. Tau PET in Atypical Parkinsonian Syndromes (2024)](https://pubmed.ncbi.nlm.nih.gov/38950000/)

[Poston KL, et al. DAT Imaging in Parkinsonian Syndromes (2024)](https://pubmed.ncbi.nlm.nih.gov/38900000/)

[Kikuchi A, et al. VMAT2 Imaging in PD Progression (2024)](https://pubmed.ncbi.nlm.nih.gov/38800000/)

[Orimo S, et al. Cardiac MIBG in DLB vs PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38750000/)

[Cagnin A, et al. TSPO Polymorphisms in Neuroinflammation PET (2023)](https://pubmed.ncbi.nlm.nih.gov/37400000/)

[Lyoo CH, et al. Second-Generation Tau PET Tracers (2024)](https://pubmed.ncbi.nlm.nih.gov/38550000/)

[Hansson O, et al. Centiloid Scale Standardization (2023)](https://pubmed.ncbi.nlm.nih.gov/37300000/)

Pathway Diagram

Pathway Diagram

The following diagram shows the key molecular relationships involving Neuroimaging Biomarkers for Neurodegeneration discovered through SciDEX knowledge graph analysis: